ABOUT THE COMPANY
Enhanced Performance & Fast Recovery
Welcome to Circularity Healthcare!
As the market for environmental, social, and governance (ESG) investments heat up around the world, Circularity Healthcare is leading the way and some of the most influential investment banks and private equity funds have taken notice. Learn more about our industry by reading our blog post titled ‘Most frequently administered drugs in the U.S. are not what you think!‘.
Circularity By The Numbers
Circularity is a decade-old growth-stage global biotech headquartered in Los Angeles, CA radically improving the standard of care worldwide with its proprietary platform therapeutics and transdermal delivery systems with an expanding loyal customer base. Purifying a leading greenhouse gas into already FDA-approved drugs and delivering them together with other modalities in a fully noninvasive, rapid, and affordable manner on the skin for long-term major health benefits and with significantly enhanced safety and efficacy profiles is fulfilling the promises of the Circular Carbon Economy.
Currently, Circularity is expanding upon its years-long successful pivotal clinical trials to over a dozen sites with an influential global clinical research organization involving top U.S. research institutions that promises to catapult it into a multi-billion-dollar global leader positioned to go public on a major U.S stock exchange. Global public multinationals already support our company’s goals as long-term strategic relationships with a combined $110 billion in market capital value.
Large leading commercial global networks with millions of patients under management have been waiting to receive Circularity’s D’OXYVA regulated products in over three dozen countries around the world. In these countries, our company has been running various successful test-marketing programs with our local teams for small and large health care providers; academia, pharmaceutical, and medical equipment manufacturers and distributors; and spa, wellness, and beauty outlets during the past seven years. Influential private equity funds and investment banks have expressed interest after thoroughly reviewing the company’s detailed business plans.
The decision is easy for health care professionals, patients, and insurance companies alike given the fact that our rapid, noninvasive platform drug delivery technologies are turned into lightweight, handheld, and completely painless mechanical gadgets that provide results at about 1/10th of the cost of competing modalities under 1/10th of the time. Our products boast of zero negative-side-effect reports to date even with long-term use after the initial health goals are achieved. For example, one of our most loyal customers started with our monthly auto-pay and auto-ship program back in 2012 and has never missed a month since then.
Our company has invested enough over the past nine years into obtaining the kinds of high-quality, dedicated production lines at home and in multiple countries with a capacity that can meet this extraordinarily large demand for our products. We are in close collaboration with the world’s largest producer of our platform—a simple, non-toxic, and Food and Drug Administration (FDA)-cleared pharmaceutical molecule. The strategic partnerships of our company include some of the largest public global diversified industrial multinationals with a combined market cap value of more than $110 billion. Circularity Healthcare was certified to ISO13485 international standards in 2013, which is one of the most stringent quality management systems in the world for medical device manufacturers.
We’re launching products in various sizes, including disposable iterations that can be built into clothing and space suits, as well as working to reverse the harsh effects of staying in space for even a few short days, including radiation and zero gravity. We can reformulate molecules with expired patents and give them new life with higher efficacy while reducing or even eliminating negative side effects altogether. With Circularity’s unique noninvasive skin delivery method applied anywhere on the body it significantly enhances the effects of CBD, THC, and any substances that were shelved due to gastrointestinal tract absorption issues besides over half of all medications on the market today. We essentially accelerate the speed of development significantly for a host of new drugs and even vaccines, including for COVID-19.
Circularity’s original platform business model offers vast application possibilities across the entire health care and beauty industry. It was vetted shortly after its inception in 2011 and by various leading consulting firms, including KPMG. This model was built on a hyper-growth trajectory with a razor and blade–type aftermarket, as well as a lean hybrid outsourced infrastructure, underpinned by a customized version of the standard business development capability maturity model. Our business development officer since the inception of the company has been Dr. Paul Kirkitelos, who is a former NASA Ames Research fellow, a former McKinsey executive, and a co-founder of a hedge fund and a public oil exploration company. Paul was the chief operating officer at Nobel Laureate Dr. Lou Ignarro’s nitric oxide supplement business. The famous little blue pill was the direct result of Dr. Ignarro’s groundbreaking research. Paul was the ghostwriter for Dr. Ignarro’s best-selling book called NO More Heart Disease, with the word “NO” standing for nitric oxide.
Circularity has invested millions of dollars during the past several years to obtain the kinds of critical strategic clinical evidence that allows world-class medical experts on the company’s advisory board to expand D’OXYVA’s pivotal clinical program, which is currently being expanded at multiple leading U.S. research institutions in collaboration with a world-leading global clinical research organization. Several members of our clinical and regulatory team are regularly called upon to testify in front of the FDA, and additional FDA clearances are expected on a fast-track path with a high degree of confidence.
The company’s first utility patent in the United Sates was granted in 2018 and has been vetted and evaluated by large global diversified multinationals and appraised by specialized international IP firms. With the help of the Orange County, CA office of one of the largest law firms, K&L Gates, the company’s patents are pending in multiple major countries, and new filings are under way.
Our internal sales and marketing plans were augmented with plans drafted by global, regional, and local leading public relations and marketing firms specializing in the health care industry, such as Edelman, Golin, and MediaPlanet, to name a few. Just recently, we launched a long-term collaboration with an influential global charity, EndPandemics.Earth in June of 2020 to support the reduction and hopefully elimination of certain wildlife trade, as well as take other steps to help mitigate the chances of other major pandemics. It is releasing more than hundreds of millions of ads over top news networks in just a short few months. In addition, along with our successful internal digital campaigns, we are launching campaigns with large platforms with top celebrities alongside multiple high-quality and high-performance social video campaigns reaching millions of viewers.
Circularity Healthcare’s patented and patent-pending technology, D’OXYVA® is based on the science of tapping into the micro-world of the body by targeting microcirculation, nerve activities and the detailed vessels within our system. Enjoy some of the high-quality photomicrography images across our website and newsletter emails that display just how fantastic the world of D’OXYVA is. Click the above images and check out the amazing photos from the Nikon Small World Competition.
Several major long-term trends are reshaping the healthcare industry worldwide:
- The movement towards the outpatient setting to encourage lowering healthcare budgets
- Decreasing reimbursement for hospital stays, hospital outpatient centers and treatments
- Increasing demand for proactive, patient-involved post-hospitalization care
- Increasing the role of telemedicine and telediagnostics to track patient progress and satisfaction
In addition, blockbuster pharmaceutical patents are expiring quickly, new medicine breakthroughs are decreasing, and profits are diminishing partly because of generics and the increasing cost of research and development.
The markets for health care solutions are driven by a high demand for minimally or non-invasive, ultra-portable applications with low-cost, low-risk, low-regulatory requirements and short time to market that require little or no reimbursement. D’OXYVA meets these requirements and much more.
Our people consider the following values are essential to realizing our mission as an effective and efficient organization. We at Circularity believe in a long-sought-after goal in health care: Access to a single health application that solves most short- and long-term health issues quickly, affordably, without pain, and without compromising other health aspects. Therefore, our mission is to design, develop, manufacture, and market proprietary, advanced, and affordable technologies that significantly improve quality of life by improving some of the most essential physiological functions in the body.
Our guiding objective is to serve those who empower our company to deliver the best solutions to patients and consumers who benefit from our products — including our primary stakeholders, the our recommending doctors, and the various distribution channels.
We do what we say and we say what we do to, empowering our company and our people to excel by taking absolute responsibility for every product, services, and solution.
We always listen to those with diverse backgrounds to consistently envision and create meaningful solutions that build value for all people engaged with our company.
We have built our company on the principle of innovative, lean, and collaboratively outsourced partnerships. We provide affordable products with a wide variety of benefits to people worldwide. We are conscientious of the bottom line that enables us safe, steady growth.
QUICK TO MARKET
Stakeholders praise our agility and precision as we tackle the unique challenges in a global business environment.
We share openly and directly with all stakeholders our company’s activities, including the potential benefits and risks of the products, services, and solutions we offer.
TEAMWORK & TALENT DEVELOPMENT
We are committed to building a world-class team that functions with dynamic flexibility, improves through collaborative support, and trains using the best-in-practice tools and techniques.
Reduce unwanted doctor visits, recommended and ranked top by experts!